Skip to main content

Christine Seidman seeks to harness and integrate clinical medicine and molecular technologies to define cardiovascular disease-causing gene mutations and genetic variations that increase disease risk. Seidman and her team develop and study human disease tissues, genetically engineered mouse models, and CRISPR/Cas9 genome-edited stem cells, combined with single cell and single nuclei transcriptomics, to define disease mechanisms. Major research projects focus on discovery of the genetic variants and transcriptional responses that result in dilated and hypertrophic cardiomyopathy and congenital heart disease. The team aims to translate basic research discoveries into better diagnostics and disease management strategies, as well as novel treatment opportunities.